Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerisation with potent liver cancer inhibitory activity

References

• Mühlethaler T, Gioia D, Prota AE, Sharpe ME, Cavalli A, Steinmetz MO. Comprehensive analysis of binding sites in tubulin. Angew Chem Int Ed Engl. 2021;60(24):13331–13342.
   PubMed Web of Science ®Google Scholar
• Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, Li W, Ouyang L, Wang Y. Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy. J Med Chem. 2021;64(12):7963–7990.
   PubMed Web of Science ®Google Scholar
• Yang J, Yu Y, Li Y, Yan W, Ye H, Niu L, Tang M, Wang Z, Yang Z, Pei H, et al. Cevipabulin–tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect. Sci Adv. 2021;7:eabg4168.
   PubMed Web of Science ®Google Scholar
• Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204.
   PubMed Web of Science ®Google Scholar
• Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742.
   PubMed Web of Science ®Google Scholar
• Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012;18(12):3428–3439.
   PubMed Web of Science ®Google Scholar
• Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Br J Cancer. 2014;110(9):2170–2177.
   PubMed Web of Science ®Google Scholar
• Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, et al. A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(15):3420–3427.
   PubMed Web of Science ®Google Scholar
• Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. A phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor-targeting agent. Clin Cancer Res. 2022;28(13):2789–2795.
   PubMed Web of Science ®Google Scholar
• Peng X, Ren Y, Pan W, Liu J, Chen J. Discovery of novel acridane-based tubulin polymerization inhibitors with anticancer and potential immunomodulatory effects. J Med Chem. 2023;66(1):627–640.
   PubMed Web of Science ®Google Scholar
• Puxeddu M, Wu J, Bai R, D’Ambrosio M, Nalli M, Coluccia A, Manetto S, Ciogli A, Masci D, Urbani A, et al. Induction of ferroptosis in glioblastoma and ovarian cancers by a new pyrrole tubulin assembly inhibitor. J Med Chem. 2022;65(23):15805–15818.,
   PubMedGoogle Scholar
• Ji T, Jian X, Chen L, Zeng W, Huo X, Li M, Chen P, Zhang Y, You W, Zhao P. Discovery of novel 6-p-tolyl-3-(3,4,5-trimethoxybenzyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine derivative as a potent tubulin inhibitor with promising in vivo antitumor activity. Eur J Med Chem. 2023;256:115437.
   PubMed Web of Science ®Google Scholar
• Barreca M, Spanò V, Rocca R, Bivacqua R, Abel A-C, Maruca A, Montalbano A, Raimondi MV, Tarantelli C, Gaudio E, et al. Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: further chemical modifications and potential therapeutic effects against lymphomas. Eur J Med Chem. 2022;243:114744.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Fan M, He M, Li Y, Peng Z. Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):1693–1701.
   Web of Science ®Google Scholar
• Liu R, Zhang S, Huang M, Guo Z, Li L, Li M, Wu L, Guan Q, Zhang W. Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors. Bioorg Chem. 2021;115:105220.
   PubMed Web of Science ®Google Scholar
• Song J, Wang SY, Wang X, Jia MQ, Tian XY, Fu XJ, Jin CY, Zhang SY. Discovery of a novel coumarin-dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities. Bioorg Chem. 2023;137:106580.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun M, Wang Y, Qin J, Zhang Y, Pang Y, Yao Y, Yang H, Duan Y. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency. Eur J Med Chem. 2021;225:113790.
   PubMed Web of Science ®Google Scholar
• Zhou P, Liu Y, Zhou L, Zhu K, Feng K, Zhang H, Liang Y, Jiang H, Luo C, Liu M, et al. Potent antitumor activities and structure basis of the chiral β-lactam bridged analogue of combretastatin A-4 binding to tubulin. J Med Chem. 2016;59(22):10329–10334.
   PubMed Web of Science ®Google Scholar
• Lin S, Du T, Zhang J, Wu D, Tian H, Zhang K, Jiang L, Lu D, Sheng L, Li Y, et al. Optimization of benzamide derivatives as potent and orally active tubulin inhibitors targeting the colchicine binding site. J Med Chem. 2022;65(24):16372–16391.
   PubMed Web of Science ®Google Scholar
• Zhu H, Li W, Shuai W, Liu Y, Yang L, Tan Y, Zheng T, Yao H, Xu J, Zhu Z, et al. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. Eur J Med Chem. 2021;216:113316.
   PubMed Web of Science ®Google Scholar
• Song J, Wang SH, Song CH, Zhang WX, Zhu JX, Tian XY, Fu XJ, Xu Y, Jin CY, Zhang SY. Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. Eur J Med Chem. 2022;240:114583.
   PubMed Web of Science ®Google Scholar
• Yuan S, Wang DS, Liu H, Zhang SN, Yang WG, Lv M, Zhou YX, Zhang SY, Song J, Liu HM. New drug approvals for 2021: synthesis and clinical applications. Eur J Med Chem. 2023;245(Pt 1):114898.
   PubMedGoogle Scholar
• Yuan S, Luo YQ, Zuo JH, Liu H, Li F, Yu B. New drug approvals for 2020: synthesis and clinical applications. Eur J Med Chem. 2021;215:113284.
   PubMed Web of Science ®Google Scholar
• Lang DK, Kaur R, Arora R, Saini B, Arora S. Nitrogen-containing heterocycles as anticancer agents: an overview. Anticancer Agents Med Chem. 2020;20(18):2150–2168.
   PubMed Web of Science ®Google Scholar
• Sharma A, Wakode S, Fayaz F, Khasimbi S, Pottoo FH, Kaur A. An overview of piperazine scaffold as promising nucleus for different therapeutic targets. Curr Pharm Des. 2020;26(35):4373–4385.
   PubMed Web of Science ®Google Scholar
• Prinz H, Ridder A-K, Vogel K, Böhm KJ, Ivanov I, Ghasemi JB, Aghaee E, Müller K, Heterocyclic N. (4-Phenylpiperazin-1-yl)methanones derived from phenoxazine and phenothiazine as highly potent inhibitors of tubulin polymerization. J Med Chem. 2017;60(2):749–766.
   PubMed Web of Science ®Google Scholar
• Wang L, Zheng Y, Li D, Yang J, Lei L, Yan W, Zheng W, Tang M, Shi M, Zhang R, et al. Design, synthesis, and bioactivity evaluation of dual-target inhibitors of tubulin and Src kinase guided by crystal structure. J Med Chem. 2021;64(12):8127–8141.
   PubMed Web of Science ®Google Scholar
• Povedano JM, Rallabandi R, Bai X, Ye X, Liou J, Chen H, Kim J, Xie Y, Posner B, Rice L, et al. A multipronged approach establishes covalent modification of β-tubulin as the mode of action of benzamide anti-cancer toxins. J Med Chem. 2020;63(22):14054–14066.
   PubMed Web of Science ®Google Scholar
• Yuan X-Y, Song C-H, Liu X-J, Wang X, Jia M-Q, Wang W, Liu W-B, Fu X-J, Jin C-Y, Song J, et al. Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers. Eur J Med Chem. 2023;252:115281.
   PubMed Web of Science ®Google Scholar
• Sun Y-X, Song J, Kong L-J, Sha B-B, Tian X-Y, Liu X-J, Hu T, Chen P, Zhang S-Y. Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities. Eur J Med Chem. 2022;229:114069.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu M, Man S, Ma D, Feng D, Sun Z, Guan Q, Zuo D, Wu Y, Zhang W, et al. Design, synthesis and bio-evaluation of novel 2-aryl-4-(3,4,5-trimethoxy-benzoyl)-5-substituted-1,2,3-triazoles as the tubulin polymerization inhibitors. Eur J Med Chem. 2020;186:111846.
   PubMed Web of Science ®Google Scholar
• Choi MJ, No ES, Thorat DA, Jang JW, Yang H, Lee J, Choo H, Kim SJ, Lee CS, Ko SY, et al. Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy. J Med Chem. 2013;56(22):9008–9018.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu C, Zhang X, Yu L, Gong X, Wang P. Anticancer sulfonamide hybrids that inhibit bladder cancer cells growth and migration as tubulin polymerisation inhibitors. J Enzyme Inhib Med Chem. 2019;34(1):1380–1387.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Parida SK, Murarka S, Singh P. Development of S-aryl dithiocarbamate derived novel antiproliferative compound exhibiting tubulin bundling. Bioorg Med Chem. 2022;68:116874.
   PubMed Web of Science ®Google Scholar
• Chopra A, Anderson A, Giardina C. Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis. J Biol Chem. 2014;289(5):2978–2991.
   PubMed Web of Science ®Google Scholar
• Song J, Guan YF, Liu WB, Song CH, Tian XY, Zhu T, Fu XJ, Qi YQ, Zhang SY. Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities. Eur J Med Chem. 2022;238:114467.
   PubMed Web of Science ®Google Scholar